Cargando…

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study

SIMPLE SUMMARY: Everolimus is an oral drug used in patients with advanced hormone receptor positive, HER2 negative breast cancer. In this study based on a national French real-world cohort of more than 22,000 patients, we sought to evaluate the impact of everolimus on overall survival. Using statist...

Descripción completa

Detalles Bibliográficos
Autores principales:	François-Martin, Hélène, Lardy-Cléaud, Audrey, Pistilli, Barbara, Levy, Christelle, Diéras, Véronique, Frenel, Jean-Sébastien, Guiu, Séverine, Mouret-Reynier, Marie-Ange, Mailliez, Audrey, Eymard, Jean-Christophe, Petit, Thierry, Ung, Mony, Desmoulins, Isabelle, Augereau, Paule, Bachelot, Thomas, Uwer, Lionel, Debled, Marc, Ferrero, Jean-Marc, Clatot, Florian, Goncalves, Anthony, Chevrot, Michael, Chabaud, Sylvie, Cottu, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954606/ https://www.ncbi.nlm.nih.gov/pubmed/36831532 http://dx.doi.org/10.3390/cancers15041191

Ejemplares similares

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
por: Mailliez, Audrey, et al.
Publicado: (2022)

Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
por: Mallet, Amélie, et al.
Publicado: (2022)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
por: Frank, Sophie, et al.
Publicado: (2020)

Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
por: Carausu, Marcela, et al.
Publicado: (2022)

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
por: Vasseur, Antoine, et al.
Publicado: (2022)

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
por: Darlix, Amélie, et al.
Publicado: (2019)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
por: Grinda, T., et al.
Publicado: (2021)

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)
por: Dano, D., et al.
Publicado: (2021)

Impact of body mass index on overall survival in patients with metastatic breast cancer
por: Saleh, Khalil, et al.
Publicado: (2020)

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
por: Sirieix, Junien, et al.
Publicado: (2020)

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
por: Cabel, Luc, et al.
Publicado: (2021)

CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
por: Gougis, P., et al.
Publicado: (2019)

Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes
por: Nguyen Van Long, Flora, et al.
Publicado: (2018)

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Bortolini Silveira, Amanda, et al.
Publicado: (2021)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients
por: Jobard, Elodie, et al.
Publicado: (2017)

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
por: Guiu, S., et al.
Publicado: (2013)

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging
por: Dejust, Sebastien, et al.
Publicado: (2018)

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
por: Lefebvre, Celine, et al.
Publicado: (2016)

Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
por: Bertho, Marion, et al.
Publicado: (2021)

Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles
por: Labriffe, Marc, et al.
Publicado: (2022)

VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
por: Gal, Jocelyn, et al.
Publicado: (2020)

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
por: Coudert, Bruno, et al.
Publicado: (2020)

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
por: Carausu, M., et al.
Publicado: (2021)

TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer
por: Gay-Bellile, Mathilde, et al.
Publicado: (2017)

Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes
por: Billaud, Amandine, et al.
Publicado: (2021)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial
por: Arroyo, Diego A, et al.
Publicado: (2018)

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients
por: Manuel, Manuarii, et al.
Publicado: (2012)

Effectiveness of a Global Multidisciplinary Supportive and Educational Intervention in Thermal Resort on Anthropometric and Biological Parameters, and the Disease-Free Survival after Breast Cancer Treatment Completion (PACThe)
por: Vasson, Marie-Paule, et al.
Publicado: (2020)

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome
por: Rochefort, Pauline, et al.
Publicado: (2017)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna(®) Test in the management of early-stage breast cancers
por: Hequet, Delphine, et al.
Publicado: (2017)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
por: Arroyo, Diego, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sn3kd1q3s1m5q101ckgefi2jk4